Clinical Trial Units
At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Our Clinical Trial Units
We run five UKCRC fully-registered specialist clinical trials units, supporting national, multinational and multicentre trials, ranging from phase I to phase IV.
Clinical Trial Management
Careers in clinical trial management, details of training and development courses and guidance for anyone interested in pursuing a career in trial management.
Participate in a Clinical Trial
If you are interested in participating in a clinical trial, this page contains links to Clinical Trial Units across the University and NHS that maybe recruiting participants.
Latest Clinical Trial News
World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group
13 July 2026
The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.
Patient enrolment begins in PARTNERS trial to identify the first effective treatments for Bundibugyo virus disease
2 July 2026
Patient enrolment has begun in the Democratic Republic of the Congo for the PARTNERS clinical trial of treatments for Bundibugyo virus disease (BVD). The trial is led in the DRC by the Institute National pour la Recherche Biomedicale, supported by the Institute of Tropical Medicine in Belgium, Ministry of Public Health of the Democratic Republic of the Congo, ALIMA (The Alliance for International Medical Action) and outbreak response teams from Médecins Sans Frontières (MSF). International trial coordination is led by the Pandemic Sciences Institute at the University of Oxford.
First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford
9 June 2026
Phase 1 of the INTERCEPT-Lynch trial, which is funded by Moderna, sponsored by the University of Oxford and run by the University's Oncology Clinical Trials Office with support from Oxford Cancer, has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.